Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Assisted Rapid Weight Loss Program for Idiopathic Intracranial Hypertension
NCT06027567Phase 4Completed
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in idiopathic intracranial hypertension (IIH) and obesity (2 arms). Primary endpoints: Body Weight at 8 weeks and Intracranial Pressure at 8 weeks. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)obesity
Beyond the preview
Go deeper on NCT06027567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027567.